(Q57696067)
Statements
Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience (English)
0 references
1 January 1994
0 references
20
0 references
4
0 references